Novartis Tagged With Anti-monopoly Conditions In China For Alcon Acquisition
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - China's growing assertiveness in commercial matters is becoming evident in its influence on merger and acquisitions matters and its willingness to impose conditions under its two-year-old anti-monopoly law
You may also be interested in...
Nestle To Become No. 1 In China's Infant Formula Market Following Pfizer Nutrition Acquisition
With roughly 60% of Pfizer Nutrition sales coming from Asia, and 47% of that from China, Nestle slips into No. 1 spot in China’s infant formula market.
Nestle To Become No. 1 In China's Infant Formula Market Following Pfizer Nutrition Acquisition
With roughly 60% of Pfizer Nutrition sales coming from Asia, and 47% of that from China, Nestle slips into No. 1 spot in China’s infant formula market.
China's MOFCOM Promises Increased Scrutiny Over M&A In 2012
China Ministry of Commerce announcement of increased M&A scrutiny, sends companies scrambling to submit papers in fear of bureaucratic delays.